Elm Street Ventures

Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Cybrexa, Inc. is focused on developing innovative DNA repair inhibitors aimed at enhancing cancer therapeutics through the use of peptide-based technology that directly targets the tumor microenvironment. Established in 2016 and based in New Haven, Connecticut, the company leverages a unique tumor-localizing peptide technology developed at Yale University. This approach aims to revolutionize drug delivery by improving the therapeutic index, allowing for safer administration of higher doses of chemotherapy and radiotherapy. Cybrexa's pipeline includes a collection of small molecule inhibitors that can be combined with existing anticancer agents, thereby expanding treatment options for patients and addressing significant unmet medical needs in oncology. Through its research, Cybrexa seeks to improve patient outcomes and redefine the landscape of cancer treatment.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Zid is an e-commerce in a box - solution that any retailer can use to start their eRetail. Zid helps them to build their own eStores (with their own name and identity) and integrates them with the supply chain players to enable them to manage and with ease. The company aims to enable the retail sector to enter the world of electronic retail in an easy and professional. Zid was founded in 2017 and based in Riyadh, Ar Riyad, Saudi Arabia.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Saphlux, Inc. is a company focused on the development, production, and commercialization of semi-polar gallium nitride (GaN) materials and micro-LED technologies. Founded in 2014 and headquartered in New Haven, Connecticut, Saphlux addresses key issues in the LED and laser industries, such as droop and green gap problems, by offering semi-polar GaN templates in various sizes. Additionally, Saphlux is a pioneer in quantum dot (QD) micro-LED solutions, designing and manufacturing micro-LED chips and micro-display modules for diverse applications, including automotive displays and augmented reality glasses. Their current product offerings include the NPQD R1 chip for public information displays and the NPQD T1 micro-display for AR applications. Operating globally, Saphlux has established a presence in the United States, China, and Japan, aiming to enhance the efficiency and performance of LED products while maintaining competitive pricing.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

SeeClickFix, Inc. is a communications platform designed to facilitate the reporting of non-emergency issues by citizens and enable governments to effectively track, manage, and respond to these reports. The company provides a suite of tools aimed at enhancing transparency, collaboration, and civic engagement within communities. Key offerings include Request Management for efficient data collection and communication, Work Management for managing assignments and internal communication, and Citizen Engagement tools that keep residents informed. Additionally, SeeClickFix offers data analytics solutions to measure success and provide insights for decision-making. The platform is designed to accommodate various community sizes and budgets, thereby empowering citizens and government entities to work together toward improving neighborhoods. Founded in 2007 and based in New Haven, Connecticut, SeeClickFix operates as a subsidiary of CivicPlus, LLC.

Device42, Inc. specializes in providing software solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, the company offers tools for patch panel cable management, IT inventory management, data center power management, and IP address tracking. Its platform includes features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a Data Center Infrastructure Management (DCIM) Software Marketplace, which helps organizations maintain an accurate inventory of both IP-based and non-IP assets. Device42's software supports various documentation needs for physical, virtual, and clustered devices, facilitating effective management of hybrid IT environments, cloud migrations, and compliance with internal and external requirements.

Device42, Inc. specializes in providing software solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, the company offers tools for patch panel cable management, IT inventory management, data center power management, and IP address tracking. Its platform includes features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a Data Center Infrastructure Management (DCIM) Software Marketplace, which helps organizations maintain an accurate inventory of both IP-based and non-IP assets. Device42's software supports various documentation needs for physical, virtual, and clustered devices, facilitating effective management of hybrid IT environments, cloud migrations, and compliance with internal and external requirements.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of therapies designed to degrade disease-causing proteins. The company’s lead product candidates include ARV-110, a proteolysis-targeting chimera (PROTAC) currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. Additionally, Arvinas is developing other PROTACs aimed at degrading various androgen receptor mutations and has initiatives focused on treating neurodegenerative diseases, including tauopathies. Arvinas collaborates with major pharmaceutical companies such as Pfizer, Genentech, Roche, and Bayer to advance its innovative therapeutic approaches. Founded in 2015, Arvinas is dedicated to improving the lives of patients with debilitating and life-threatening conditions through its unique protein degradation technology.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Desmos, Inc. is a San Francisco-based company that offers a web-based graphing calculator designed for educational purposes. Founded in 2007 and originally named Tutor Trove, LLC, the company aims to enhance mathematical learning for students and teachers in the United States and internationally. Its platform provides users with the ability to graph functions, plot data tables, evaluate equations, and explore mathematical transformations. By delivering a platform-agnostic software solution, Desmos bridges the gap between different classrooms and facilitates a connection between classroom learning and home study. The interactive graphing platform features a robust math engine that allows users to instantly plot various mathematical equations, making math more accessible and engaging for learners.

Accelerated Orthopedic Technologies, Inc., based in Guilford, Connecticut, specializes in developing proprietary instruments designed to treat articular cartilage defects. The company focuses on creating custom-sized tools that match the specific shapes and topographies required for effective cartilage grafting. Originally incorporated in 2009 under the name Advanced Orthopedic Technologies, the company underwent a rebranding in February 2010 to its current name. With a commitment to innovation, Accelerated Orthopedic Technologies aims to enhance surgical outcomes in orthopedic procedures involving cartilage repair.

Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds. Among the indications under investigation are cancer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

ShareGrove operates an online conversations platform that enables users to engage with friends from Facebook and other social networks in a dynamic and media-rich environment. The platform allows for both real-time and asynchronous interactions, all managed through a single web interface. Users can enhance their conversations with integrated web searches from sources such as Google, Amazon, and Yelp, which also facilitates revenue generation through affiliate programs. By combining these features, ShareGrove aims to create a seamless and engaging communication experience for its users.

Retail Optimization Inc. provides predictive macro optimization analytics to determine the most profitable levels of product selection, category space and inventory investment while enhancing the shopping experience for consumers.

Affomix has proprietary technology for rapid, automated, high-throughput selection of human monoclonal antibodies (mAbs). Their mission is to commercialize proprietary mAbs, mAb microarrays and mAb libraries for research, drug discovery, diagnostic and therapeutic applications, with a particular focus on the use of their mAbs for sensitive and accurate measurement of very large numbers of proteins in biological samples.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.